PhRMA campaign touts Part D positives

Share this article:
PhRMA campaign touts Part D positives
PhRMA campaign touts Part D positives
PhRMA launched a national TV ad campaign aimed in part at dissuading congressional Democrats from tampering with the Medicare Part D prescription drug benefit to allow the government to negotiate drug prices.

The ad celebrates the successes of Medicare Part D, and asks viewers to call 202-224-3121 and “tell Congress we need quality affordable healthcare coverage for every American.”

“All across America, over 26 million seniors have signed up for Medicare drug coverage, choosing a private plan that fits their needs, and saving an average of $1,200.00 a year on their prescription medicine,” says the ad's narrator. “And with competition holding down costs, taxpayers are saving billions. The Medicare benefit is working, and seniors are happy.”

According to a PhRMA release, the campaign touts “the importance and success of free-market initiatives such as [Medicare Part D].” The “free-market” elements of Medicare Part D – in particular, a policy provision barring Medicare from negotiating drug prices with manufacturers – have been challenged anew by congressional Democrats.

Two bills introduced in Congress last January, one in the House (H.R.684) and one in Senate (S.330), by Rep. Robert Berry (D-AR) and Sen. Richard Durbin (D-IL), respectively, would empower government officials to “negotiate with pharmaceutical manufactures with respect to the purchase price of covered part D drugs.”
Share this article:

Email Newsletters

More in News

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?

In sunny world of LASIK marketers, a dark underbelly

In sunny world of LASIK marketers, a dark ...

Last week, the former FDA branch chief who originally approved LASIK machines asked FDA to reconsider its denial last month of his petition to ban these devices.

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.